1-氮杂二环[2.2.2]辛-2-烯,3-(三丁基甲锡烷基)- | 154183-72-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1-氮杂二环[2.2.2]辛-2-烯,3-(三丁基甲锡烷基)-
• 英文名称: 3-Tributylstannyl-quinuclidin-2-ene
• 英文别名: 3-tributylstannanyl-1-aza-bicyclo[2.2.2]oct-2-ene；3-(Tributylstannyl)-1-azabicyclo[2.2.2]oct-2-ene；1-azabicyclo[2.2.2]oct-2-en-3-yl(tributyl)stannane
• CAS: 154183-72-9
• 化学式: C₁₉H₃₇NSn
• 分子量: 398.219
• InChiKey: VBNXFJLTVSOYFY-UHFFFAOYSA-N

物化性质

• 沸点：
  399.8±35.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.98
• 重原子数：
  21
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-溴-2-糠酸甲酯 、 1-氮杂二环[2.2.2]辛-2-烯,3-(三丁基甲锡烷基)- 在 bis-triphenylphosphine-palladium(II) chloride 作用下， 以 1,4-二氧六环 为溶剂， 反应 120.0h， 以37%的产率得到3-(5-methoxycarbonyl-2-furyl)-quinuclidin-2-ene
  参考文献：
  名称：

  Antimuscarinic 3-(2-Furanyl)quinuclidin-2-ene Derivatives:  Synthesis and Structure−Activity Relationships

  摘要：

  A series of 25 derivatives of the muscarinic antagonist 3-(2-furanyl)quinuclidin-2-ene (4) was synthesized and evaluated for muscarinic and antimuscarinic properties. Substitution at all three positions of the furan ring has been investigated. The affinities of the new compounds were determined by competition experiments in homogenates of cerebral cortex, heart, parotid gland, and urinary bladder from guinea pigs using (-)-[H-3]-3-quinuclidinyl benzilate as the radioligand, and the antimuscarinic potency was determined in a functional assay on isolated guinea pig urinary bladder using carbachol as the agonist. Several of the novel derivatives displayed high muscarinic affinities. Whereas the affinity of lead compound 4 for cortical muscarinic receptors is moderate (K-i 300 nM), it is much higher for the 6-methyl (49; K-i = 12 nM), 5-ethyl (52; K-i = 7.4 nM), 5-bromo (33; K-i = 6.4 nM), and 3-phenyl (49; K-i = 2.8 nM) substituted derivatives. The substituent-induced increases in affinity do not appear to be additive as a 5-bromo-3-phenyl (54), and a 5-methyl-3-phenyl (55) substitution pattern only slightly increases affinity (K-i = 1.55 and 2.39 nM, respectively). The conformational preferences of the 3-phenyl (49) and 5-phenyl (51) derivatives were studied by X-ray crystallography and molecular mechanics calculations. Because of the observed high affinity of 49, a series of 16 meta-and para-substituted analogues of 49 was synthesized and tested. derivative (68) exhibited more than 10-fold improvement in affinity as compared to 49. The structure-activity relationships of the new series are well described with QSAR and CoMFA models.

  DOI：

  10.1021/jm970346t

文献信息

• [EN] NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER<br/>[FR] NOUVEAUX DERIVES DE BENZOFURANE, POUVANT ETRE UTILISES DANS LA PROPHYLAXIE OU LE TRAITEMENT DES AFFECTIONS ASSOCIEES AU RECEPTEUR DE 5-HT6
  申请人：BIOVITRUM AB

  公开号：WO2005058858A1

  公开（公告）日：2005-06-30

  The present invention relates to compounds of formula (I): wherein P, R3, W1, and W2 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.

  本发明涉及公式（I）的化合物：其中P、R3、W1和W2如本文所述，以及包含这些化合物的药物组合物，用于它们的制备过程，以及用于制备针对5-HT6受体相关疾病的药物的化合物的用途。
• Compounds
  申请人：Johansson Gary

  公开号：US20060287291A1

  公开（公告）日：2006-12-21

  The present invention relates to compounds of formula (I): wherein P, R 3 , W 1 , and W 2 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT 6 receptor-related disorders.

  本发明涉及式(I)的化合物：其中P、R3、W1和W2如此描述，以及包含该化合物的制药组合物，其制备过程，以及用于制备针对5-HT6受体相关疾病的药物的化合物的使用。
• Benzofuran compounds
  申请人：Biovitrum AB

  公开号：US07820675B2

  公开（公告）日：2010-10-26

  The present invention relates to compounds of formula (I): wherein P, R3, W1, and W2 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.

  本发明涉及式(I)的化合物：其中P、R3、W1和W2如本文所述，以及包含该化合物的制药组合物、其制备过程，以及该化合物用于制备用于对抗5-HT6受体相关疾病的药物的用途。
• Benzofuran Compounds
  申请人：Johansson Gary

  公开号：US20110015185A1

  公开（公告）日：2011-01-20

  The present invention relates to compounds of formula (I): wherein P, R 3 , W 1 , and W 2 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT 6 receptor-related disorders.

  本发明涉及公式（I）的化合物：其中P，R3，W1和W2如本文所述，以及包含该化合物的制药组合物，其制备过程，以及该化合物用于制备针对5-HT6受体相关疾病的药物的用途。